DE60101739D1 - Makrolide - Google Patents

Makrolide

Info

Publication number
DE60101739D1
DE60101739D1 DE60101739T DE60101739T DE60101739D1 DE 60101739 D1 DE60101739 D1 DE 60101739D1 DE 60101739 T DE60101739 T DE 60101739T DE 60101739 T DE60101739 T DE 60101739T DE 60101739 D1 DE60101739 D1 DE 60101739D1
Authority
DE
Germany
Prior art keywords
macrolides
macrolactam
pimecrolimus
epimerization
concomitant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60101739T
Other languages
English (en)
Other versions
DE60101739T2 (de
Inventor
Gerhard Fleissner
Helmut Haecker
Ernst Kuesters
Gerhard Penn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60101739D1 publication Critical patent/DE60101739D1/de
Publication of DE60101739T2 publication Critical patent/DE60101739T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrane Compounds (AREA)
DE60101739T 2000-05-22 2001-05-21 Makrolide Expired - Lifetime DE60101739T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0012383.6A GB0012383D0 (en) 2000-05-22 2000-05-22 Organic compounds
GB0012383 2000-05-22
PCT/EP2001/005836 WO2001090110A1 (en) 2000-05-22 2001-05-21 Macrolides

Publications (2)

Publication Number Publication Date
DE60101739D1 true DE60101739D1 (de) 2004-02-12
DE60101739T2 DE60101739T2 (de) 2004-12-09

Family

ID=9892108

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60101739T Expired - Lifetime DE60101739T2 (de) 2000-05-22 2001-05-21 Makrolide

Country Status (15)

Country Link
US (1) US6706727B1 (de)
EP (1) EP1289997B1 (de)
JP (2) JP4043239B2 (de)
CN (1) CN1229381C (de)
AT (1) ATE257481T1 (de)
AU (1) AU2001278428A1 (de)
CA (1) CA2405593C (de)
DE (1) DE60101739T2 (de)
DK (1) DK1289997T3 (de)
ES (1) ES2214436T3 (de)
GB (1) GB0012383D0 (de)
HK (1) HK1054945A1 (de)
PT (1) PT1289997E (de)
TR (1) TR200400723T4 (de)
WO (1) WO2001090110A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9618952D0 (en) * 1996-09-11 1996-10-23 Sandoz Ltd Process
CA2442969A1 (en) * 2001-05-09 2002-11-14 Novartis Ag Methods for selective immunomodulation using pimecrolimus
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds
EP1539041A1 (de) * 2002-07-25 2005-06-15 Avantec Vascular Corporation Vorrichtungen zur abgabe von therapeutischen mitteln und relevante verfahren
EP1740168A2 (de) * 2004-04-21 2007-01-10 Advanced Ocular Systems Limited Antiprostaglandine zur behandlung von augenpathologien
EP1768662A2 (de) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner moleküle und assays für deren nachweis
GT200500282A (es) * 2004-10-12 2006-05-04 Heteroatomos conteniendo compuestos triciclicos.
WO2006060614A1 (en) * 2004-12-01 2006-06-08 Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg Methods for preparing pimecrolimus
CN104250255B (zh) * 2013-06-28 2016-05-25 北京大学 一种柔性内酰胺类大环分子及其制备方法
US10975097B2 (en) 2017-05-01 2021-04-13 Meda Ab Process to convert technical ascomycin into purified pimecrolimus
EP3741367A1 (de) 2019-05-21 2020-11-25 Premark Pharma GmbH Behandlung von augenerkrankungen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430455D0 (en) * 1984-12-03 1985-01-09 Fujisawa Pharmaceutical Co Fr-900506 substance
NZ235991A (en) * 1989-11-09 1993-05-26 Sandoz Ltd Macrolide compounds and pharmaceutical compositions thereof
JP3362394B2 (ja) * 1995-09-19 2003-01-07 藤沢薬品工業株式会社 エアゾール組成物
DK1056454T3 (da) * 1998-02-23 2003-08-18 Fujisawa Pharmaceutical Co Anvendelse af makrolidforbindelser til behandling af glaukom

Also Published As

Publication number Publication date
CA2405593A1 (en) 2001-11-29
JP2003534345A (ja) 2003-11-18
JP4043239B2 (ja) 2008-02-06
ES2214436T3 (es) 2004-09-16
TR200400723T4 (tr) 2004-06-21
HK1054945A1 (en) 2003-12-19
EP1289997B1 (de) 2004-01-07
DE60101739T2 (de) 2004-12-09
EP1289997A1 (de) 2003-03-12
CA2405593C (en) 2009-12-22
WO2001090110A1 (en) 2001-11-29
GB0012383D0 (en) 2000-07-12
ATE257481T1 (de) 2004-01-15
US6706727B1 (en) 2004-03-16
JP2007254483A (ja) 2007-10-04
CN1430620A (zh) 2003-07-16
DK1289997T3 (da) 2004-05-10
PT1289997E (pt) 2004-05-31
AU2001278428A1 (en) 2001-12-03
CN1229381C (zh) 2005-11-30

Similar Documents

Publication Publication Date Title
ID22162A (id) Penggunaan turunan-turunan pirazol yang dilebur 1-benzil-3-(hetaril yang disubstitusik)
BR0113643A (pt) Compostos de guanidinobenzamidas como agonistas de mc4-r e seus usos
IL176110A0 (en) Azabicyclic heterocycles as cannabinoid receptor modulators
HN1998000143A (es) Tetrahidronaftalenos substituidos y compuestos analogos.
ATE360630T1 (de) Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
ATE166534T1 (de) Germicide wirkstoffkombinationen
FI953748A (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
MY137156A (en) Dual nk1/nk3 derivatives
PA8432901A1 (es) Compuestos de piridilpirrol
DE60101739D1 (de) Makrolide
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
ATE340184T1 (de) Makrolidantibiotika
BRPI0017528B8 (pt) uso de uma composição contendo sal de cetotifeno
NZ503897A (en) 3,6-hemiketals from the class of 9a-azalides
NZ332321A (en) 3-Descladinose-2,3-anhydroerythromycin derivatives and medicaments
ES8701193A1 (es) Un procedimiento para preparar derivados de acido griseolico
AP9801377A0 (en) Tricyclic erythromycin derivatives.
IL110831A0 (en) Quinazolinone-containing pharmaceutical compositions and methods for the use thereof
CO5011051A1 (es) Compuesto de carbapenem, uso del mismo y sus compuestos intermedios
UY28535A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
UA41350C2 (uk) Похідна морфоліну або її фармацевтично прийнятна сіль та фармацевтична композиція на її основі
PA8522201A1 (es) Derivados de pirrolidina
DK0802920T3 (da) Fusacandin-antisvampemidler

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN